Novo Nordisk Guards the 'OZEMPIC' Franchise
Mar/04/2026
On March 3, Novo Nordisk filed a U.S. opposition against the trademark 'OZEMPATCH', registered for stationery products such as notebooks, pens, and calendars, arguing that the name too closely echoes its blockbuster 'OZEMPIC' brand. The move comes amid mounting pressure on the Danish drugmaker’s obesity franchise. Telehealth firm Hims & Hers recently scrapped plans to market a compounded version of Novo’s weight-loss pill after regulatory scrutiny and legal threats, while federal authorities signaled tougher action against copycat GLP-1 drugs. At the same time, Novo faces intensifying competition from Eli Lilly after clinical trials showed its next-generation treatment, CagriSema, trailing Lilly’s tirzepatide in head-to-head weight-loss results—an outcome that has unsettled investors and underscored the strategic importance of protecting the Ozempic name.
Latest Surveys
-
Novo Nordisk Guards the 'OZEMPIC' Franchise
Mar/04/2026 -
Honda Recasts Its Emblem for an Electric Future
Jan/23/2026
